Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
Rang in Aktien #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Aktienkurs
$1.51
Zuletzt synchronisiert: 2024-08-26
Marktkapitalisierung
$1.12M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Agile Therapeutics, Inc. (AGRX)

Kategorie

Gewinn für Agile Therapeutics, Inc. (AGRX)
Gewinn im Jun 2024 TTM: $-15.86M
Laut den aktuellen Finanzberichten von Agile Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $-15.86M. Im Jahr 2022 erzielte das Unternehmen einen Gewinn von $-30.09M, eine Steigerung gegenüber dem Gewinn im Jahr 2021, der $-74.89M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Agile Therapeutics, Inc. von 2012 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-15.86M 9.62%
2023 $-14.47M -51.92%
2022 $-30.09M -59.83%
2021 $-74.89M 44.44%
2020 $-51.85M 178.69%
2019 $-18.61M -8.15%
2018 $-20.26M -28.43%
2017 $-28.30M -11.04%
2016 $-31.82M -12.37%
2015 $-36.31M 84.02%
2014 $-19.73M 37.77%
2013 $-14.32M -38.43%
2012 $-23.26M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten